Trials / Completed
CompletedNCT03362112
Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,713 (actual)
- Sponsor
- Nanjing First Hospital, Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
Lipoprotein-associated phospholipase A2 (LP-PLA2) is a good marker of cardiovascular risk and inflammation. This study aims at the characteristic and clinical significance of LP-PLA2 test in patients with type 2 diabetes(T2D).
Detailed description
The investigators recorded clinical factors, serum levels of glucose, HbA1c, lipids and LP-PLA2 in patients with T2D who visited in the Department of Endocrinology at the Nanjing First Hospital from January 2015 to August 2016. The relationship between levels of LP-PLA2 and diabetic complications are analysed.
Conditions
Timeline
- Start date
- 2015-01-30
- Primary completion
- 2016-08-31
- Completion
- 2017-06-01
- First posted
- 2017-12-05
- Last updated
- 2022-04-14
- Results posted
- 2022-04-14
Source: ClinicalTrials.gov record NCT03362112. Inclusion in this directory is not an endorsement.